ALK-Abelló A/S
AKBLF
Other OTC37.92
USD
- -
- -
ALK-Abelló A/S
AKBLF
(Other OTC)
Recent
price
37.92
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- ALK-Abelló A/S is a Denmark-based global specialty pharmaceutical company focused on the development, manufacturing, and marketing of allergy immunotherapy (AIT) products and other allergy treatment solutions. The company’s core product portfolio includes sublingual immunotherapy tablets (SLIT-tablets) for grass pollen, ragweed pollen, and house dust mite allergies; sublingual immunotherapy drops (SLIT-drops) covering approximately 40 different allergens including pollens, molds, mites, and pets; and subcutaneous immunotherapy injections (SCIT) for common allergens such as pollens, molds, mites, pets, bees, and wasps. Additionally, ALK offers an emergency adrenaline autoinjector for anaphylaxis management, allergy diagnostic kits such as skin prick tests, and bulk allergen extracts primarily sold to allergy specialists in the U.S. The company operates worldwide with production facilities and subsidiaries across Europe, North America, and Asia, including Denmark, France, Spain, and multiple U.S. locations. Founded in 1923, ALK is headquartered in Hørsholm, Denmark. In recent strategic developments, ALK completed the acquisition of the business assets of AllerQuest in January 2024, making ALK the sole manufacturer and distributor of PRE-PEN, an allergy treatment product in the U.S. and Canada, with global ownership rights. In November 2024, ALK entered into a strategic licensing agreement with U.S.-based ARS Pharmaceuticals granting ALK exclusive global rights (excluding the US, Australia, New Zealand, Japan, and China) to the neffy® adrenaline nasal spray, with upfront payments and potential milestone-based payments structured over the coming years. ALK has also expanded its partnership with Abbott into several South-East Asian growth markets and continues to grow through collaborations, aiming to enhance its global market presence. The company recently expanded its executive leadership team to strengthen focus on key commercial regions. ALK’s main industry segment is pharmaceutical allergy treatments, targeting allergy sufferers and allergy healthcare professionals globally. The company’s products serve markets in Europe, North America, Asia Pacific, and other international regions supported by direct operations and partnerships. ALK emphasizes research and development on patient-friendly allergy immunotherapy, including its pioneering SLIT-tablets which re-educate the immune system to treat the underlying allergy causes. The Lundbeck Foundation is among its significant shareholders. ALK employs approximately 2,900 people worldwide and maintains extensive production and R&D facilities, reinforcing its position as a global leader in allergy immunotherapy solutions offering comprehensive allergy prevention, diagnosis, and treatment products and services. This description reflects ALK-Abelló’s latest operational scale, strategic acquisitions, partnerships, and product offerings as of late 2025.
ALK-Abelló A/S (AKBLF) Q1 2026 Earnings Call Transcript
ALK-Abelló A/S (AKBLF) Shareholder/Analyst Call Transcript
ALK-Abelló A/S (AKBLF) Q4 2025 Earnings Call Transcript
Invitation to the presentation of ALK's annual report 2025 on Friday, 20 February 2026
ALK-Abelló A/S (OTC:AKBLF) Trading Up 1.8% – What’s Next?
ALK-Abelló A/S (AKBLF) Q3 2025 Earnings Call Transcript
ALK-Abelló A/S (AKBLF) Q2 2025 Earnings Call Transcript
ALK-Abelló A/S (AKBLF) Q1 2025 Earnings Call Transcript
ALK-Abelló A/S (AKBLF) Q4 2024 Earnings Call Transcript
ALK-Abelló A/S (AKBLF) Q3 2024 Earnings Conference Call Transcript
ALK-Abelló A/S (AKBLF) Q1 2024 Earnings Call Transcript